5-HT receptor

The 5-HT_1B receptor as an example of a metabotropic serotonin receptor. Its crystallographic structure in ribbon representation

5-HT receptors, 5-hydroxytryptamine receptors, or serotonin receptors, are a group of G protein-coupled receptor and ligand-gated ion channels found in the central and peripheral nervous systems.[1][2][3] They mediate both excitatory and inhibitory neurotransmission. The serotonin (i.e., 5-hydroxytryptamine, hence "5-HT") receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand.

The serotonin receptors modulate the release of many neurotransmitters, including glutamate, GABA, dopamine, epinephrine / norepinephrine, and acetylcholine, as well as many hormones, including oxytocin, prolactin, vasopressin, cortisol, corticotropin, and substance P, among others. Serotonin receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation. They are the target of a variety of pharmaceutical and recreational drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.[4]

Serotonin receptors are found in almost all animals and are even known to regulate longevity and behavioral aging in the primitive nematode, Caenorhabditis elegans.[5][6]

Classification

5-hydroxytryptamine receptors or 5-HT receptors, or serotonin receptors are found in the central and peripheral nervous systems.[1][2] They can be divided into 7 families of G protein-coupled receptors which activate an intracellular second messenger cascade to produce an excitatory or inhibitory response. The exception to this is the 5-HT₃ receptor which is a ligand-gated ion channel. In 2014, a novel 5-HT receptor was isolated from the small white butterfly, Pieris rapae, and named pr5-HT₈. It does not occur in mammals and shares relatively low similarity to the known 5-HT receptor classes.[7]

Families

Family	Type	Mechanism	Potential
5-HT1	Gi/Go-protein coupled.	Decreasing cellular levels of cAMP.	Inhibitory
5-HT2	Gq/G11-protein coupled.	Increasing cellular levels of IP3 and DAG.	Excitatory
5-HT3	Ligand-gated Na^+ and K^+ cation channel.	Depolarizing plasma membrane.	Excitatory
5-HT4	Gs-protein coupled.	Increasing cellular levels of cAMP.	Excitatory
5-HT5	Gi/Go-protein coupled.[8]	Decreasing cellular levels of cAMP.	Inhibitory
5-HT6	Gs-protein coupled.	Increasing cellular levels of cAMP.	Excitatory
5-HT7	Gs-protein coupled.	Increasing cellular levels of cAMP.	Excitatory

Subtypes

The 7 general serotonin receptor classes include a total of 14 known serotonin receptors.[9] The 15th receptor 5-HT_1P has been distinguished on the basis of functional and radioligand binding studies, its existence has never been definitely affirmed or refuted.[10][11] The specific types have been characterized as follows:[12][13][14]

Information on serotonin receptors (human isoforms if nothing else is stated)
Receptor	First cloned – PDB entries	Gene(s)	Distribution						Function	Agonists	Antagonists	Uses of drugs that act on this receptor
			Blood vessels	CNS	GI Tract	Platelets	PNS	Smooth Muscle
5-HT1A	1987 – 7e2x 7e2y 7e2z	HTR1A	Yes	Yes	No	No	No	No	Addiction[15][16][17] Aggression[18] Anxiety[19] Appetite[20] Autoreceptor Blood Pressure[21][22] Cardiovascular Function[23] Emesis[24] Heart Rate[21][22] Impulsivity[25] Memory[26][27] Mood[28] Nausea[24] Nociception[29] Penile Erection[30] Pupil Dilation[31] Respiration[32] Sexual Behavior[33] Sleep[34] Sociability[35] Thermoregulation[36] Vasoconstriction[37]	Selective (for 5-HT1A over other 5-HT receptors) Vilazodone (Viibryd) F-15,599 (research compound, highly potent and selective for 5-HT1A) Flesinoxan (potent, EC50 = 24 nM) Gepirone (partial agonist, Ki = 70 nM) Haloperidol Ipsapirone (partial agonist, Ki = 12.1 nM) Quetiapine Trazodone (SARI, selective in the sense that on all other 5-HT receptors it acts as either an antagonist or has no action. Kd = 78 nM) Yohimbine (unselective partial agonist) Tandospirone (potent and selective partial agonist) Nonselective 5-CT (potent – Ki = 250 ± 50 pM) 8-OH-DPAT (potent) Aripiprazole (atypical antipsychotic) Asenapine (atypical antipsychotic) Buspirone[38] (partial agonist) Vortioxetine (high-efficacy partial agonist)[39] Ziprasidone (partial agonist, Ki = 3.4 nM) Methylphenidate (weak agonist)	BMY 7378 Cyanopindolol Iodocyanopindolol Lecozotan Methiothepin Methysergide[40] NAN-190 Nebivolol Nefazodone WAY-100,135 WAY-100,635 Mefway	Analgesics (agonists) Antidepressants (post-synaptic receptor agonists and pre-synaptic autoreceptor antagonists serve as antidepressants) Anxiolytics[41] (agonist and antagonist)
5-HT1B	1992 – 6g79	HTR1B	Yes	Yes	No	No	No	No	Addiction[42] Aggression[18] Anxiety[43][44][45] Autoreceptor Learning[46] Locomotion[47] Memory[46] Mood[45] Penile Erection[30] Sexual Behavior[33] Vasoconstriction	5-CT CGS-12066A CP-93,129 CP-94,253 Dihydroergotamine Eltoprazine Ergotamine Methysergide RU 24969 TFMPP Triptans[38] (antimigraine[38]) Zolmitriptan Eletriptan Sumatriptan Vortioxetine (partial agonist, Ki = 33 nM)[39]	Alprenolol AR-A000002 Asenapine Cyanopindolol GR-127,935 Iodocyanopindolol Isamoltane Metergoline Methiothepin Oxprenolol Pindolol Propranolol SB-216,641 Yohimbine	Migraines (e.g., triptans)
5-HT1D	1991 – 7e32	HTR1D	Yes	Yes	No	No	No	No	Anxiety[48][49] Autoreceptor Locomotion[47] Vasoconstriction	5-CT CP-135,807 Dihydroergotamine Ergotamine Methysergide Triptans[38] (antimigraine[38]) Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan Zolmitriptan Yohimbine	BRL-15572 GR-127,935 Ketanserin Metergoline Methiothepin Rauwolscine Ritanserin Vortioxetine (Ki = 54 nM)[39] Ziprasidone	Migraines (e.g., triptans)
5-HT1E	1992 – 7e33	HTR1E	Yes	Yes	No	No	No	No		BRL-54443		None known
5-HT1F	1993 – 7exd	HTR1F	No	Yes	No	No	No	No	Migraine	BRL-54443 Lasmiditan LY-334,370 Naratriptan Eletriptan		None known
5-HT1P	Not cloned		No	No	Yes	No	No	No	Peristalsis[11][50]	5-OHIP[11][51] 2-Methyl-5-HT[52] 5-BOHIP[53]	5-HTP-DP[11]	None known
5-HT2A	1988	HTR2A	Yes	Yes	Yes	Yes	Yes	Yes	Addiction (potentially modulating)[54] Anxiety[55] Appetite Cognition Imagination Learning Memory Mood Perception Sexual Behavior[56] Sleep[57] Thermoregulation[58] Vasoconstriction[59]	25I-NBOMe (Full agonist) 2C-B 2C-I 5-MeO-DMT Aripiprazole (very weak partial agonist or antagonist) BZP Bufotenin DMT DOM Ergonovine Lisuride LSD Mescaline PNU-22394 (partial agonist)[60][61][62] Psilocin Psilocybin TFMPP (partial agonist or antagonist)	Atypical antipsychotics Clozapine[38] Olanzapine Quetiapine Risperidone Ziprasidone Asenapine Amitriptyline Clomipramine Cyproheptadine Doxepin Eplivanserin Etoperidone Haloperidol Hydroxyzine Iloperidone Ketanserin[38] (antihypertensive[38]) Methysergide Mianserin Mirtazapine Nefazodone Pimavanserin Pizotifen Ritanserin Trazodone Yohimbine	Atypical antipsychotics (antagonist) Psychedelics (agonists) NaSSAs (antidepressants and anxiolytics; they serve as antagonists at this site) Treating serotonin syndrome (antagonists; e.g., cyproheptadine) Sleeping aid (antagonists; e.g., trazodone)
5-HT2B	1992	HTR2B	Yes	Yes	Yes	Yes	Yes	Yes	Anxiety[63][64][65] Appetite[66] Cardiovascular Function GI Motility[67] Sleep[57] Vasoconstriction	6-APB (full agonist) BW-723C86 Fenfluramine MDMA Norfenfluramine PNU-22394 (partial agonist)[60][61][62] Ro60-0175 Methylphenidate (weak agonist)	Agomelatine Asenapine BZP Ketanserin Methysergide Ritanserin RS-127,445 Tegaserod Yohimbine	Migraines (antagonists)
5-HT2C	1988	HTR2C	Yes	Yes	Yes	Yes	Yes	Yes	Addiction (potentially modulating)[54] Anxiety[68][69][70] Appetite GI Motility[71] Heteroreceptor for norepinephrine and dopamine Locomotion Mood[69][70] Penile Erection[72][73] Sexual Behavior[56] Sleep[74] Thermoregulation[58] Vasoconstriction	2C-B (partial agonist)[75] A-372,159 AL-38022A Aripiprazole Ergonovine Lorcaserin PNU-22394 (full agonist)[60][61][62] Ro60-0175 TFMPP Trazodone[38] (hypnotic[38]) YM-348	Agomelatine[38] (antidepressant[38]) Amitriptyline Asenapine Clomipramine Clozapine[38] (antipsychotic[38]) Cyproheptadine Dimebolin Eltoprazine Etoperidone Fluoxetine Haloperidol Iloperidone Ketanserin[38] (antihypertensive[38]) Lisuride Methysergide[76] Mianserin Mirtazapine Nefazodone Olanzapine Paroxetine Quetiapine Risperidone Ritanserin SB-242084 Tramadol Trazodone Ziprasidone	Antidepressant (antagonists; e.g., agomelatine, fluoxetine, mirtazapine) Orexigenic (e.g., mirtazapine, clozapine and olanzapine; antagonists) Anorectic (Lorcaserin; agonist) Antipsychotic (Vabicaserin; agonists)
5-HT3	1993	HTR3A HTR3B HTR3C HTR3D HTR3E	No	Yes	Yes	No	Yes	No	Addiction Anxiety Emesis GI Motility[77] Learning[78] Memory[78] Nausea	2-Methyl-5-HT BZP Quipazine RS-56812	Alosetron Several antiemetics[38] Dolasetron Ondansetron[38] Granisetron Tropisetron Clozapine Memantine Metoclopramide Mianserin Mirtazapine Olanzapine Quetiapine Vortioxetine (Ki = 3.7 nM)[39]	Antiemetic Antidepressant (e.g., mirtazpine) antipsychotic (e.g., olanzapine, quetiapine)
5-HT4	1995	HTR4	No	Yes	Yes	No	Yes	No	Anxiety[79][80] Appetite[81][82] GI Motility Learning[83][84] Memory[83][84][85] Mood[86][87] Respiration[88]	5-MT BIMU-8 Cinitapride Cisapride[38] (gastroprokinetic) Dazopride Metoclopramide Mosapride Prucalopride RS-67333 Renzapride Tegaserod Zacopride	L-Lysine[79] Piboserod	Gastroprokinetics (e.g., Tegaserod)
5-HT5A	1994 7UM4 7UM5 7UM6 7UM7	HTR5A	No	Yes	No	No	No	No	Autoreceptor Locomotion[89] Sleep[90]	5-CT Ergotamine Lisuride (partial)[91] Methylergometrine (full)[91] Valerenic Acid (partial agonist)[90]	Asenapine Dimebolin Methiothepin Ritanserin SB-699,551 SB-699,551-A MS112[91]	None thus far
5-HT5B	1993	HTR5BP	No	No	No	No	No	No	Functions in rodents, pseudogene in humans			None thus far
5-HT6	1993	HTR6	No	Yes	No	No	No	No	Anxiety[92][93] Cognition[94] Learning[95] Memory[95] Mood[93][96]	EMD-386,088 EMDT WAY-181,187 WAY-208,466 E-6837 N-(inden-5-yl)imidazothiazole-5-sulfonamide (43)[97]	Amitriptyline Aripiprazole Asenapine Clomipramine Clozapine Dimebolin EGIS-12233 Haloperidol Iloperidone MS-245 Olanzapine Ro04-6790 SB-258,585 SB-271,046[98] SB-357,134 SB-399,885	Antidepressant (antagonists and agonists) Anxiolytic (antagonists and agonist) Nootropic (antagonists) Anorectic (antagonists)
5-HT7	1993	HTR7	Yes	Yes	Yes	No	No	No	Anxiety[99][100] Autoreceptor Memory[101][102] Mood[99][100] Respiration[32][103] Sleep[99][103][104] Thermoregulation Vasoconstriction Immunostimulation[105]	5-CT 8-OH-DPAT Aripiprazole (partial agonist)[106] AS-19 E-55888	Amitriptyline Asenapine Clomipramine Clozapine EGIS-12233 Haloperidol Iloperidone Imipramine Ketanserin Mirtazapine Olanzapine RA-7 Ritanserin Risperidone SB-269,970 Vortioxetine (Ki = 19 nM)[39]	Antidepressant (antagonists) Anxiolytics (antagonists) Nootropic (antagonists)

Note that there is no 5-HT_1C receptor since, after the receptor was cloned and further characterized, it was found to have more in common with the 5-HT₂ family of receptors and was redesignated as the 5-HT_2C receptor.[107]

Very nonselective agonists of 5-HT receptor subtypes include ergotamine (an antimigraine), which activates 5-HT_1A, 5-HT_1D, 5-HT_1B, D₂ and norepinephrine receptors.[38] LSD (a psychedelic) is a 5-HT_1A, 5-HT_2A, 5-HT_2C, 5-HT_5A and 5-HT₆ agonist.[38]

Expression patterns

The genes coding for serotonin receptors are expressed across the mammalian brain. Genes coding for different receptors types follow different developmental curves. Specifically, there is a developmental increase of HTR5A expression in several subregions of the human cortex, paralleled by a decreased expression of HTR1A from the embryonic period to the post-natal one. [108]

5-HT₁-like

A number of receptors were classed as "5-HT₁-like" - by 1998 it was being argued that, since these receptors were "a heterogeneous population of 5-HT1B, 5-HT1D and 5-HT7" receptors the classification was redundant.[109]

References

1. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. (June 1994). "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)". Pharmacological Reviews. 46 (2): 157–203. PMID 7938165.
2. Frazer A, Hensler JG (1999). "Chapter 13: Serotonin Receptors". In Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds.). Basic Neurochemistry: MolecularCellular, and Medical Aspects. Philadelphia: Lippincott-Raven. pp. 263–292. ISBN 978-0-397-51820-3.
3. Beliveau V, Ganz M, Feng L, Ozenne B, Højgaard L, Fisher PM, et al. (January 2017). "A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System". The Journal of Neuroscience. 37 (1): 120–128. doi:10.1523/jneurosci.2830-16.2016. PMC 5214625. PMID 28053035.
4. Nichols DE, Nichols CD (May 2008). "Serotonin receptors". Chemical Reviews. 108 (5): 1614–1641. doi:10.1021/cr078224o. PMID 18476671.
5. Murakami H, Murakami S (August 2007). "Serotonin receptors antagonistically modulate Caenorhabditis elegans longevity". Aging Cell. 6 (4): 483–488. doi:10.1111/j.1474-9726.2007.00303.x. PMID 17559503. S2CID 8345654.
6. Murakami H, Bessinger K, Hellmann J, Murakami S (July 2008). "Manipulation of serotonin signal suppresses early phase of behavioral aging in Caenorhabditis elegans". Neurobiology of Aging. 29 (7): 1093–1100. doi:10.1016/j.neurobiolaging.2007.01.013. PMID 17336425. S2CID 37671716.
7. Qi YX, Xia RY, Wu YS, Stanley D, Huang J, Ye GY (December 2014). "Larvae of the small white butterfly, Pieris rapae, express a novel serotonin receptor". Journal of Neurochemistry. 131 (6): 767–777. doi:10.1111/jnc.12940. PMID 25187179. S2CID 21621635.
8. Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE (November 1998). "The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells". European Journal of Pharmacology. 361 (2–3): 299–309. doi:10.1016/S0014-2999(98)00744-4. PMID 9865521.
9. Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 4. ISBN 9780071481274. Similarly, little is known about which of serotonin's 14 known receptors must be activated to achieve an antidepressant response.
10. Brady ST (2012). Basic Neurochemistry - Principles of Molecular, Cellular and Medical Neurobiology (8th ed.). Waltham, MA: USA: Elsevier. pp. 320–321. ISBN 978-0-12-374947-5.
11. Mitchell NA, Pepperell E, Ociepka S, Brown JD, Witherington J, Tuladhar B, et al. (July 2009). "5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon". Neurogastroenterology and Motility. 21 (7): 760–e48. doi:10.1111/j.1365-2982.2009.01275.x. PMID 19309442. S2CID 9532359.
12. Glennon RA, Dukat M, Westkaemper RB (2000-01-01). "Serotonin Receptor Subtypes and Ligands". American College of Neurophyscopharmacology. Archived from the original on 21 April 2008. Retrieved 2008-04-11.
13. "5-Hydroxytryptamine Receptors". IUPHAR Receptor Database. International Union of Basic and Clinical Pharmacology. Retrieved 2008-04-11.
14. Wesołowska A (2002). "In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors" (PDF). Polish Journal of Pharmacology. 54 (4): 327–341. PMID 12523486.
15. Tomkins DM, Higgins GA, Sellers EM (June 1994). "Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake". Psychopharmacology. 115 (1–2): 173–179. doi:10.1007/BF02244769. PMID 7862892. S2CID 38012716.
16. Müller CP, Carey RJ, Huston JP, De Souza Silva MA (February 2007). "Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors". Progress in Neurobiology. 81 (3): 133–178. doi:10.1016/j.pneurobio.2007.01.001. PMID 17316955. S2CID 42788995.
17. Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP (February 2005). "Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects". Brain Research. 1034 (1–2): 162–171. doi:10.1016/j.brainres.2004.12.012. PMID 15713268. S2CID 28356741.
18. de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". European Journal of Pharmacology. 526 (1–3): 125–139. doi:10.1016/j.ejphar.2005.09.065. PMID 16310183.
19. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (September 1998). "Increased anxiety of mice lacking the serotonin1A receptor". Proceedings of the National Academy of Sciences of the United States of America. 95 (18): 10734–10739. Bibcode:1998PNAS...9510734P. doi:10.1073/pnas.95.18.10734. PMC 27964. PMID 9724773.
20. Ebenezer IS, Arkle MJ, Tite RM (May 2007). "8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors". Methods and Findings in Experimental and Clinical Pharmacology. 29 (4): 269–272. doi:10.1358/mf.2007.29.4.1075362. PMID 17609739.
21. Wouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors". European Journal of Pharmacology. 149 (3): 213–223. doi:10.1016/0014-2999(88)90651-6. PMID 2842163.
22. Horiuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–76. doi:10.1016/j.autneu.2008.06.004. PMID 18667366. S2CID 20878941.
23. Nalivaiko E, Ootsuka Y, Blessing WW (August 2005). "Activation of 5-HT1A receptors in the medullary raphe reduces cardiovascular changes elicited by acute psychological and inflammatory stresses in rabbits". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 289 (2): R596–R604. doi:10.1152/ajpregu.00845.2004. PMID 15802554. S2CID 17426759.
24. Lucot JB (February 1994). "Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin". European Journal of Pharmacology. 253 (1–2): 53–60. doi:10.1016/0014-2999(94)90756-0. PMID 8013549.
25. Winstanley CA, Theobald DE, Dalley JW, Robbins TW (April 2005). "Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders". Neuropsychopharmacology. 30 (4): 669–682. doi:10.1038/sj.npp.1300610. PMID 15688093.
26. Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, et al. (December 2008). "The role of 5-HT(1A) receptors in learning and memory". Behavioural Brain Research. 195 (1): 54–77. doi:10.1016/j.bbr.2008.02.023. PMID 18394726. S2CID 140205386.
27. Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, et al. (February 2003). "Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory". The American Journal of Psychiatry. 160 (2): 334–340. doi:10.1176/appi.ajp.160.2.334. PMID 12562581.
28. Kennett GA, Dourish CT, Curzon G (February 1987). "Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression". European Journal of Pharmacology. 134 (3): 265–274. doi:10.1016/0014-2999(87)90357-8. PMID 2883013.
29. Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC (April 2003). "Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain". Pharmacology. 67 (4): 182–194. doi:10.1159/000068404. PMID 12595749. S2CID 25882138.
30. Millan MJ, Perrin-Monneyron S (March 1997). "Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 321 (3): R11–R13. doi:10.1016/S0014-2999(97)00050-2. PMID 9085055.
31. Prow MR, Martin KF, Heal DJ (December 1996). "8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation". European Journal of Pharmacology. 317 (1): 21–28. doi:10.1016/S0014-2999(96)00693-0. PMID 8982715.
32. Meyer LC, Fuller A, Mitchell D (February 2006). "Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 290 (2): R405–R413. doi:10.1152/ajpregu.00440.2005. PMID 16166206. S2CID 224414.
33. Popova NK, Amstislavskaya TG (July 2002). "Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice". Psychoneuroendocrinology. 27 (5): 609–618. doi:10.1016/S0306-4530(01)00097-X. PMID 11965359. S2CID 25269315.
34. Monti JM, Jantos H (September 1992). "Dose-dependent effects of the 5-HT1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat". Journal of Sleep Research. 1 (3): 169–175. doi:10.1111/j.1365-2869.1992.tb00033.x. PMID 10607047.
35. Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). "A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")". Neuroscience. 146 (2): 509–514. doi:10.1016/j.neuroscience.2007.02.032. PMID 17383105. S2CID 15617471.
36. Gudelsky GA, Koenig JI, Meltzer HY (December 1986). "Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors". Neuropharmacology. 25 (12): 1307–1313. doi:10.1016/0028-3908(86)90101-2. PMID 2951611. S2CID 2547042.
37. Ootsuka Y, Blessing WW (February 2006). "Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits". Brain Research. 1073–1074: 252–261. doi:10.1016/j.brainres.2005.12.031. PMID 16455061. S2CID 23178233.
38. Pharmacology Corner > Serotonin (5-HT): receptors, agonists and antagonists By Flavio Guzmán, M.D. on 9/08/09
39. "BRINTELLIX (vortioxetine) tablets for oral use. Full Prescribing Information, Section 12.2 (Pharmacodynamics)." Takeda Pharmaceuticals America Inc. and Lundbeck, 2013. Revised September 2013. [1] Archived 2019-09-18 at the Wayback Machine
40. Saxena PR, Lawang A (October 1985). "A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors". Archives Internationales de Pharmacodynamie et de Therapie. 277 (2): 235–252. PMID 2933009.
41. Cao BJ, Rodgers RJ (October 1998). "Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice". Psychopharmacology. 139 (3): 185–194. doi:10.1007/s002130050703. PMID 9784072. S2CID 9466299.
42. Harrison AA, Parsons LH, Koob GF, Markou A (January 1999). "RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist". Psychopharmacology. 141 (3): 242–250. doi:10.1007/s002130050831. PMID 10027505. S2CID 19974789.
43. Chojnacka-Wójcik E, Kłodzińska A, Tatarczyńska E (February 2005). "The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action". The Journal of Pharmacy and Pharmacology. 57 (2): 253–257. doi:10.1211/0022357055399. PMID 15720791. S2CID 20743875.
44. Lin D, Parsons LH (April 2002). "Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze". Pharmacology, Biochemistry, and Behavior. 71 (4): 581–587. doi:10.1016/S0091-3057(01)00712-2. PMID 11888549. S2CID 21610537.
45. Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E (December 2004). "Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression". Behavioural Pharmacology. 15 (8): 523–534. doi:10.1097/00008877-200412000-00001. PMID 15577451. S2CID 6940756.
46. Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ogren SO (June 2008). "Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission". Neuropharmacology. 54 (7): 1041–1050. doi:10.1016/j.neuropharm.2008.02.007. hdl:10616/40922. PMID 18394658. S2CID 207223573.
47. McCreary AC, Bankson MG, Cunningham KA (September 1999). "Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors". The Journal of Pharmacology and Experimental Therapeutics. 290 (3): 965–973. PMID 10454466.
48. Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J (May 2005). "Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study". European Neuropsychopharmacology. 15 (3): 279–282. doi:10.1016/j.euroneuro.2004.12.002. PMID 15820416. S2CID 8382188.
49. Feuerstein TJ, Hüring H, van Velthoven V, Lücking CH, Landwehrmeyer GB (May 1996). "5-HT1D-like receptors inhibit the release of endogenously formed [3H]GABA in human, but not in rabbit, neocortex". Neuroscience Letters. 209 (3): 210–214. doi:10.1016/0304-3940(96)12637-9. PMID 8736648. S2CID 27376524.
50. Najjar SA, Hung LY, Margolis KG (June 2023). "Serotonergic Control of Gastrointestinal Development, Motility, and Inflammation". Comprehensive Physiology. 13 (3): 4851–4868. doi:10.1002/cphy.c220024. ISBN 9780470650714. PMC 10373054. PMID 37358510.
51. Branchek TA, Mawe GM, Gershon MD (July 1988). "Characterization and localization of a peripheral neural 5-hydroxytryptamine receptor subtype (5-HT1P) with a selective agonist, 3H-5-hydroxyindalpine". The Journal of Neuroscience. 8 (7): 2582–2595. doi:10.1523/JNEUROSCI.08-07-02582.1988. PMC 6569501. PMID 3249244.
52. Mawe GM, Branchek TA, Gershon MD (December 1986). "Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists". Proceedings of the National Academy of Sciences of the United States of America. 83 (24): 9799–9803. Bibcode:1986PNAS...83.9799M. doi:10.1073/pnas.83.24.9799. PMC 387229. PMID 3467338.
53. Annaházi, Anita; Berger, Thomas Erwin; Demir, Ihsan Ekin; Zeller, Florian; Müller, Michael; Anneser, Markus; Skerra, Arne; Michel, Klaus; Schemann, Michael (April 2022). "Metabotropic 5-HT receptor-mediated effects in the human submucous plexus". Neurogastroenterology & Motility. 34 (10): e14380. doi:10.1111/nmo.14380. ISSN 1350-1925. PMID 35438222. S2CID 248241342.
54. Bubar MJ, Cunningham KA (2006). "Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence". Current Topics in Medicinal Chemistry. 6 (18): 1971–1985. doi:10.2174/156802606778522131. PMID 17017968.
55. Schreiber R, Melon C, De Vry J (February 1998). "The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test". Psychopharmacology. 135 (4): 383–391. doi:10.1007/s002130050526. PMID 9539263. S2CID 22677071.
56. Popova NK, Amstislavskaya TG (July 2002). "5-HT2A and 5-HT2C serotonin receptors differentially modulate mouse sexual arousal and the hypothalamo-pituitary-testicular response to the presence of a female". Neuroendocrinology. 76 (1): 28–34. doi:10.1159/000063681. PMID 12097814. S2CID 42319246.
57. Popa D, Léna C, Fabre V, Prenat C, Gingrich J, Escourrou P, et al. (December 2005). "Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors". The Journal of Neuroscience. 25 (49): 11231–11238. doi:10.1523/JNEUROSCI.1724-05.2005. PMC 6725907. PMID 16339018.
58. Mazzola-Pomietto P, Aulakh CS, Tolliver T, Murphy DL (March 1997). "Functional subsensitivity of 5-HT2A and 5-HT2C receptors mediating hyperthermia following acute and chronic treatment with 5-HT2A/2C receptor antagonists". Psychopharmacology. 130 (2): 144–151. doi:10.1007/s002130050222. PMID 9106912. S2CID 22432569.
59. Blessing WW, Seaman B (2003). "5-hydroxytryptamine(2A) receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats". Neuroscience. 117 (4): 939–948. doi:10.1016/S0306-4522(02)00810-2. PMID 12654345. S2CID 53251590.
60. McCall RB, Franklin SR, Hyslop DK, Knauer CS, Chio CL, Haber CL, Fitzgerald LW (2001). PNU-22394, a 5-HT2C receptor agonist, reduced feeding in rodents and produces weight loss in humans (Online). Society for Neuroscience. Vol. 27. Presentation Number 309.2. San Diego, CA: Society for Neuroscience Abstracts. p. TT-45. Retrieved 18 July 2014.
61. Garfield AS, Heisler LK (January 2009). "Pharmacological targeting of the serotonergic system for the treatment of obesity". The Journal of Physiology. 587 (1): 49–60. doi:10.1113/jphysiol.2008.164152. PMC 2670022. PMID 19029184.
62. Jensen AA, Plath N, Pedersen MH, Isberg V, Krall J, Wellendorph P, et al. (February 2013). "Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties". Journal of Medicinal Chemistry. 56 (3): 1211–1227. CiteSeerX 10.1.1.691.154. doi:10.1021/jm301656h. PMID 23301527.
63. Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP (April 1996). "Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety". British Journal of Pharmacology. 117 (7): 1443–1448. doi:10.1111/j.1476-5381.1996.tb15304.x. PMC 1909458. PMID 8730737.
64. Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC (1997). "Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat". Neuropharmacology. 36 (4–5): 601–608. doi:10.1016/S0028-3908(97)00042-7. PMID 9225285. S2CID 41471226.
65. Kennett GA, Trail B, Bright F (December 1998). "Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated". Neuropharmacology. 37 (12): 1603–1610. doi:10.1016/S0028-3908(98)00115-4. PMID 9886683. S2CID 7310462.
66. Kennett GA, Ainsworth K, Trail B, Blackburn TP (February 1997). "BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats". Neuropharmacology. 36 (2): 233–239. doi:10.1016/S0028-3908(96)00171-2. PMID 9144661. S2CID 23583570.
67. Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, et al. (March 2002). "5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro". British Journal of Pharmacology. 135 (5): 1144–1151. doi:10.1038/sj.bjp.0704571. PMC 1573235. PMID 11877320.
68. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, et al. (1997). "SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist". Neuropharmacology. 36 (4–5): 609–620. doi:10.1016/S0028-3908(97)00038-5. PMID 9225286. S2CID 23032157.
69. Millan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–458. doi:10.1007/s00213-004-1962-z. PMID 15289999. S2CID 20866665.
70. Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, et al. (September 2008). "S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models". Psychopharmacology. 199 (4): 549–568. doi:10.1007/s00213-008-1177-9. PMID 18523738. S2CID 25063495.
71. Fujitsuka N, Asakawa A, Hayashi M, Sameshima M, Amitani H, Kojima S, et al. (May 2009). "Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin". Biological Psychiatry. 65 (9): 748–759. doi:10.1016/j.biopsych.2008.10.031. PMID 19058784. S2CID 22053616.
72. Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S (April 1997). "5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists". European Journal of Pharmacology. 325 (1): 9–12. doi:10.1016/S0014-2999(97)89962-1. PMID 9151932.
73. Stancampiano R, Melis MR, Argiolas A (August 1994). "Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission". European Journal of Pharmacology. 261 (1–2): 149–155. doi:10.1016/0014-2999(94)90313-1. PMID 8001637.
74. Frank MG, Stryker MP, Tecott LH (November 2002). "Sleep and sleep homeostasis in mice lacking the 5-HT2c receptor". Neuropsychopharmacology. 27 (5): 869–873. doi:10.1016/S0893-133X(02)00353-6. PMC 2452994. PMID 12431861.
75. Villalobos CA, Bull P, Sáez P, Cassels BK, Huidobro-Toro JP (April 2004). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes". British Journal of Pharmacology. 141 (7): 1167–1174. doi:10.1038/sj.bjp.0705722. PMC 1574890. PMID 15006903.
76. Rang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 978-0-443-07145-4. Page 187
77. Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, et al. (May 2005). "Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors". Gastroenterology. 128 (5): 1317–1326. doi:10.1053/j.gastro.2005.02.005. PMID 15887114.
78. Pitsikas N, Brambilla A, Borsini F (January 1994). "Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task". Pharmacology, Biochemistry, and Behavior. 47 (1): 95–99. doi:10.1016/0091-3057(94)90116-3. PMID 8115433. S2CID 21800364.
79. Smriga M, Torii K (December 2003). "L-Lysine acts like a partial serotonin receptor 4 antagonist and inhibits serotonin-mediated intestinal pathologies and anxiety in rats". Proceedings of the National Academy of Sciences of the United States of America. 100 (26): 15370–15375. Bibcode:2003PNAS..10015370S. doi:10.1073/pnas.2436556100. PMC 307574. PMID 14676321.
80. Kennett GA, Bright F, Trail B, Blackburn TP, Sanger GJ (1997). "Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats". Neuropharmacology. 36 (4–5): 707–712. doi:10.1016/S0028-3908(97)00037-3. PMID 9225297. S2CID 40341646.
81. Jean A, Conductier G, Manrique C, Bouras C, Berta P, Hen R, et al. (October 2007). "Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens". Proceedings of the National Academy of Sciences of the United States of America. 104 (41): 16335–16340. Bibcode:2007PNAS..10416335J. doi:10.1073/pnas.0701471104. PMC 2042207. PMID 17913892.
82. Compan V, Charnay Y, Dusticier N, Daszuta A, Hen R, Bockaert J (2004). "[Feeding disorders in 5-HT4 receptor knockout mice]". Journal de la Société de Biologie. 198 (1): 37–49. doi:10.1051/jbio/2004198010037. PMID 15146954. S2CID 90408378.
83. Meneses A, Hong E (March 1997). "Effects of 5-HT4 receptor agonists and antagonists in learning". Pharmacology, Biochemistry, and Behavior. 56 (3): 347–351. doi:10.1016/S0091-3057(96)00224-9. PMID 9077568. S2CID 11866740.
84. Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM (1997). "The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation". Neuropharmacology. 36 (4–5): 689–696. doi:10.1016/S0028-3908(97)00055-5. PMID 9225295. S2CID 46510811.
85. Galeotti N, Ghelardini C, Bartolini A (September 1998). "Role of 5-HT4 receptors in the mouse passive avoidance test". The Journal of Pharmacology and Experimental Therapeutics. 286 (3): 1115–1121. PMID 9732367.
86. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, et al. (September 2007). "Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action". Neuron. 55 (5): 712–725. doi:10.1016/j.neuron.2007.07.041. PMID 17785179. S2CID 14558104.
87. Duman RS (September 2007). "A silver bullet for the treatment of depression?". Neuron. 55 (5): 679–681. doi:10.1016/j.neuron.2007.08.011. PMID 17785173.
88. Manzke T, Guenther U, Ponimaskin EG, Haller M, Dutschmann M, Schwarzacher S, Richter DW (July 2003). "5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia". Science. 301 (5630): 226–229. Bibcode:2003Sci...301..226M. doi:10.1126/science.1084674. PMID 12855812. S2CID 13641423.
89. Nelson DL (February 2004). "5-HT5 receptors". Current Drug Targets. CNS and Neurological Disorders. 3 (1): 53–58. doi:10.2174/1568007043482606. PMID 14965244.
90. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR (August 2005). "Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro". Brain Research. Molecular Brain Research. 138 (2): 191–197. doi:10.1016/j.molbrainres.2005.04.009. PMC 5805132. PMID 15921820.
91. Zhang S, Chen H, Zhang C, Yang Y, Popov P, Liu J, et al. (July 2022). "Inactive and active state structures template selective tools for the human 5-HT_5A receptor". Nature Structural & Molecular Biology. 29 (7): 677–687. doi:10.1038/s41594-022-00796-6. PMC 9299520. PMID 35835867.
92. Wesołowska A (February 2008). "The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors". European Journal of Pharmacology. 580 (3): 355–360. doi:10.1016/j.ejphar.2007.11.022. PMID 18096153.
93. Wesołowska A, Nikiforuk A (April 2007). "Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression". Neuropharmacology. 52 (5): 1274–1283. doi:10.1016/j.neuropharm.2007.01.007. PMID 17320917. S2CID 22664564.
94. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, et al. (December 2006). "SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models". European Journal of Pharmacology. 553 (1–3): 109–119. doi:10.1016/j.ejphar.2006.09.049. PMID 17069795.
95. Perez-García G, Meneses A (July 2005). "Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task". Pharmacology, Biochemistry, and Behavior. 81 (3): 673–682. doi:10.1016/j.pbb.2005.05.005. PMID 15964617. S2CID 19789219.
96. Wesołowska A, Nikiforuk A (March 2008). "The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats". European Journal of Pharmacology. 582 (1–3): 88–93. doi:10.1016/j.ejphar.2007.12.013. PMID 18234190.
97. Alcalde E, Mesquida N, López-Pérez S, Frigola J, Mercè R (Feb 2009). "Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT₆ serotonin receptor agonists". Journal of Medicinal Chemistry. 52 (3): 675–87. doi:10.1021/jm8009469. PMID 19159187.
98. "Target Schizophrenia - Possible future developments". The Association of the British Pharmaceutical Industry. Archived from the original on 2008-06-12. Retrieved 2008-04-11.
99. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG (November 2005). "5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern". Biological Psychiatry. 58 (10): 831–837. doi:10.1016/j.biopsych.2005.05.012. PMID 16018977. S2CID 10998014.
100. Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (September 2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–586. doi:10.1016/j.neuropharm.2006.04.017. PMID 16828124. S2CID 39928418.
101. Gasbarri A, Cifariello A, Pompili A, Meneses A (December 2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–170. doi:10.1016/j.bbr.2007.12.020. PMID 18308404. S2CID 12910296.
102. Liy-Salmeron G, Meneses A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–974. doi:10.1002/hipo.20459. PMID 18570192. S2CID 20937527.
103. Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, et al. (May 2007). "Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents". The Journal of Pharmacology and Experimental Therapeutics. 321 (2): 690–698. doi:10.1124/jpet.107.119404. PMID 17314195. S2CID 14579645.
104. Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, et al. (June 2003). "SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats". British Journal of Pharmacology. 139 (4): 705–714. doi:10.1038/sj.bjp.0705290. PMC 1573887. PMID 12812993.
105. León-Ponte, Matilde; Ahern, Gerard P.; O'Connell, Peta J. (2007-04-15). "Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor". Blood. 109 (8): 3139–3146. doi:10.1182/blood-2006-10-052787. ISSN 0006-4971. PMC 1852236. PMID 17158224.
106. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf
107. "HTR2C 5-hydroxytryptamine receptor 2C [ Homo sapiens (human) ]". NCBI. 19 Mar 2017. Retrieved 26 Mar 2017.
108. Bar-Shira O, Maor R, Chechik G (December 2015). "Gene Expression Switching of Receptor Subunits in Human Brain Development". PLOS Computational Biology. 11 (12): e1004559. Bibcode:2015PLSCB..11E4559B. doi:10.1371/journal.pcbi.1004559. PMC 4670163. PMID 26636753.
109. Saxena PR, De Vries P, Villalón CM (August 1998). "5-HT1-like receptors: a time to bid goodbye". Trends in Pharmacological Sciences. 19 (8): 311–316. doi:10.1016/S0165-6147(98)01228-0. PMID 9745358.

External links

• Serotonin+Receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• "5-Hydroxytryptamine Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
• Rubenstein LA, Lanzara RG (2005-02-16). "Activation of G protein-coupled receptors entails cysteine modulation of agonist binding". Cogprints. Retrieved 2008-04-11.
• Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM (January 2013). "5-HT radioligands for human brain imaging with PET and SPECT". Medicinal Research Reviews. 33 (1): 54–111. doi:10.1002/med.20245. PMC 4188513. PMID 21674551.